Literature DB >> 7860235

Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.

A Hantel1, C M Tangen, J S Macdonald, S P Richman, R P Pugh, T Pollock.   

Abstract

Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0-22%). Hematologic toxicities of grade > or = 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7860235     DOI： 10.1007/bf00874448

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  Cancer statistics, 1994.

Authors:  C C Boring; T S Squires; T Tong; S Montgomery
Journal:  CA Cancer J Clin       Date:  1994 Jan-Feb       Impact factor: 508.702

2.  Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.

Authors:  F J Panettiere; C Haas; B McDonald; J J Costanzi; R W Talley; J Athens; N Oishi; L K Heilbrun; T T Chen
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

3.  2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.

Authors:  J R Bertino; W L Sawicki; B A Moroson; A R Cashmore; E F Elslager
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

4.  Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro.

Authors:  B A Kamen; B Eibl; A Cashmore; J Bertino
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

5.  Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

Authors:  H Diddens; D Niethammer; R C Jackson
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

6.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.

Authors:  S Green; G R Weiss
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850
  6 in total
  1 in total

Review 1.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.